Financial PerformanceKamada reported in-line financial results for their 1Q25, including revenues of $44.0 million, or 17% above those of 1Q24, and net income of $0.07 per share as compared to $0.04 per share in the prior year.
International ExpansionKamada continues the growth trajectory fueled by ex US expansion and increased demand.
Strategic InitiativesStrengthening the biosimilar portfolio is expected to yield significant revenue over the next five years, further diversifying its commercial offerings.